Comparison of Metformin and Pioglitazone Effects on Adipokines Concentrations in Newly Diagnosed Type 2 Diabetes Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

98 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-07-31

Study Completion Date

2012-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Oral hypoglycemic agents encompass the mainstay of treatment in the majority of patients with type 2 diabetes. Thiazolidinediones (such a pioglitazone) and Biguanides (such as metformin), are two major groups of hypoglycemic medications that while function via different pathways, are both effective in short- and long-term glycemic control . These medications diminish or at least delay long term micro- and macrovascular complications associated with prolonged insulin resistance although at different rates. The mechanisms by which this aim is achieved, nevertheless, remains largely unclear. With adipokines playing a key role in development of both insulin resistance and atherosclerosis, oral hypoglycemic agents might regulate these substances by direct and indirect routes.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Metformin and Pioglitazone Effects on Fetuin-A and Osteoprotegrin Concentrations in Type 2 Diabetes Patients

NCT02027103

Type 2 Diabetes Mellitus

COMPLETED NA

Pioglitazone Versus Metformin in Type 2 Diabetes

NCT00815399

Type 2 Diabetes

COMPLETED PHASE4

Metformin and Pioglitazone Effects on YKL-40 Concentrations in Type 2 Diabetes Patients

NCT01963663

Type 2 Diabetes Mellitus

COMPLETED NA

Exenatide Plus Pioglitazone Versus Insulin in Poorly Controlled T2DM

NCT02887625

Type 2 Diabetes

UNKNOWN NA

Efficacy of Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets on the Patients With Newly Diagnosed Type 2 Diabetes Mellitus Combined With Non-alcoholic Fatty Liver Disease

NCT03796975

Type 2 Diabetes Mellitus Non-alcoholic Fatty Liver Disease Efficacy

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 2 Diabetes Mellitus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Metformin

patients receiving fixed dose metformin 1000 mg daily

Group Type ACTIVE_COMPARATOR

Metformin

Intervention Type DRUG

Metformin 1000 mg fixed dose, twice daily (500 mg tablets x 2)

Pioglitazone

patients receiving fixed dose pioglitazone 30 mg daily

Group Type ACTIVE_COMPARATOR

Pioglitazone

Intervention Type DRUG

Pioglitazone 30 mg fixed dose, twice daily (15 mg tablets x 2)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Metformin

Metformin 1000 mg fixed dose, twice daily (500 mg tablets x 2)

Intervention Type DRUG

Pioglitazone

Pioglitazone 30 mg fixed dose, twice daily (15 mg tablets x 2)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Newly diagnosed type 2 diabetes patients based on American Diabetes Association criteria (2011) for diagnosis of diabetes

Exclusion Criteria

* previous intake of oral hypoglycemic agents for treatment of diabetes or other hyperglycemia associated conditions
* intake of glucocorticoids in the past one year
* major illnesses of heart, lung, kidney, and liver.

Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No